- Home
- MDCX vs GTBP Comparison
MDCX vs GTBP Comparison
Compare MDCX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | GTBP |
|---|---|---|
| Founded | 2008 | 1965 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 12.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | MDCX | GTBP |
|---|---|---|
| Price | $0.40 | $0.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $23.50 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 583.8K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.35 |
| 52 Week High | $8.90 | $3.73 |
Technical Indicators
Market Signals| Indicator | MDCX | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 38.03 |
| Support Level | $0.38 | N/A |
| Resistance Level | $0.52 | $0.46 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 17.58 | 25.80 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.